Dr. Avtar Dhillon reports

EMERALD HEALTH THERAPEUTICS DELIVERS TO YUKON AND ADDS SUPPLY AGREEMENTS WITH ALBERTA AND SASKATCHEWAN

Emerald Health Therapeutics Inc. has fulfilled its first purchase order of cannabis from Yukon Liquor Corporation, signed a sales agreement with Alberta Gaming, Liquor and Cannabis (AGLC), and become officially registered by the Saskatchewan Liquor and Gaming Authority (SLGA) to supply cannabis to the Saskatchewan market. First shipments to Alberta and Saskatchewan are expected in April.

"We are pleased to provide our Emerald-branded cannabis products to the adult-use markets in Alberta, Saskatchewan and the Yukon," said Dr. Avtar Dhillon, president and executive chairman of Emerald. "This brings the number to five provinces and one territory across Canada and is another step in our sales strategy to become a reliable national recreational cannabis supplier."

Emerald is consistently meeting its supply commitments in Ontario, British Columbia, and Newfoundland and Labrador, and is advancing prospective supply agreements with all remaining provinces and territories in order to develop a significant presence in the recreational market.

Emerald's cannabis supply is provided by its Verdelite indoor facility in Saint Eustache, Que., and Pure Sunfarms, its 50-per-cent-owned joint venture in British Columbia that is licensed to cultivate in 1.03 million square feet of its 1.1-million-square-foot greenhouse. This facility has been scaling up production over the last four quarters and will be fully planted in April. Emerald is working to expand sources and volume of indoor-, greenhouse- and outdoor-grown cannabis and hemp. In 2018, Emerald acquired 500 acres of harvested hemp and expects to purchase 1,000 acres of harvested hemp in 2019.

About Emerald Health Therapeutics Inc.

Emerald Health Therapeutics is a Canadian licensed producer of cannabis with operations in British Columbia and Quebec. Emerald has secured exclusive strategic partnerships for large-scale extraction and softgel encapsulation, as well as for proprietary technology to enhance cannabinoid bioavailability. Its team is highly experienced in life sciences, product development, large-scale agri-business and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers.

We seek Safe Harbor.